Evidence map›Paper›PMID 29057384›Full record

ArticleCurrent opinion in toxicology2017

Concise Review: Current and Emerging Biomarkers of Nephrotoxicity.

Elijah J Weber, Jonathan Himmelfarb, Edward J Kelly

Abstract read
In one paragraph

Article in Current opinion in toxicology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Gallic and Hesperidin Ameliorate Electrolyte Imbalances in AlClBiochemistry research international · 2022
    Article
  4. Review
  5. Computational toxicology (Amsterdam, Netherlands) · 2021
    Article
  6. Article
  7. Emerging Kidney Models to Investigate Metabolism, Transport, and Toxicity of Drugs and Xenobiotics.Drug metabolism and disposition: the biological fate of chemicals · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Elijah J WeberDepartment of Pharmaceutics, University of Washington, Seattle, WA, 98195.
Jonathan HimmelfarbKidney Research Institute, University of Washington, Seattle, WA, 98195.
Edward J KellyDepartment of Pharmaceutics, University of Washington, Seattle, WA, 98195.

Funding

XENOBIOTIC BIOTRANSFORMATION AND DISPOSITIONP30ES007033 · NIEHS · UNIVERSITY OF WASHINGTON · PI Nicole Ann Errett · 1995 to 2026
$42.5M
Using iPSCs to model patient outcomes in nephrotic syndromeUH3TR000504 · NCATS · UNIVERSITY OF WASHINGTON · PI HIMMELFARB, JONATHAN · 2014 to 2016
$6.1M
A Tissue Engineered Human Kidney Microphysiological SystemUH2TR000504 · NCATS · UNIVERSITY OF WASHINGTON · PI HIMMELFARB, JONATHAN · 2012 to 2013
$2.1M
NCATS NIH HHS UH2 TR000504NCATS NIH HHS UH3 TR000504NIEHS NIH HHS P30 ES007033
6 · The paper itself

Abstract

The kidney is a primary organ for filtration of the blood and elimination of drugs and xenobiotics. These active reabsorptive and secretory processes can result in acute kidney injury as a result of these concentrative properties. Classic measures of acute kidney injury are hampered by their ability to accurately assess function before irreversible damage has occurred. This review will discuss efforts to refine the clinical utility of standard biomarkers as well as the development of novel biomarkers of nephrotoxicity.

Indexed as

Acute Kidney InjuryBiomarkersNephrotoxicity

Identifiers

PMID29057384
PMCPMC5647884

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.